Next Generation Sequencing Minimal Residual Disease in Pediatric B-ALL after CD19 and/or CD22 CAR T-cell Therapy: Depth and Kinetics of Response Predict Relapse Risk.

Puntos clave

• Relapse risk is significantly influenced by the depth and kinetics of response measured post-CAR T-cell therapy.
• The study found 40% of patients experienced relapse within two years of therapy, highlighting the need for targeted monitoring.
• Assessment using next generation sequencing revealed minimal residual disease as a critical marker for predicting relapse outcomes.
• These findings emphasize the importance of response dynamics in treatment planning for pediatric B-ALL.